AspenBio Pharma, Inc. to Present at the ROTH Capital Partners 21st Annual OC Growth Stock Conference

CASTLE ROCK, CO--(Marketwire - February 06, 2009) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, has been invited to present at the 21st Annual ROTH Capital Partners OC Growth Stock Conference. The conference will be held February 16-18, 2009 at the Ritz-Carlton, Laguna Niguel in Dana Point, California.

ROTH Capital Partners Stock Conferences are among the largest in the nation for micro and small-cap companies in technology, healthcare, financial services and consumer products sectors. More than 1,000 institutional investors are expected to attend.

The company’s recently appointed executive chairman, Daryl J. Faulkner, is scheduled to present on Wednesday, February 18 at 3:30 p.m. Pacific time (6:30 p.m. Eastern time), followed by a break out session and one-on-one meetings. Faulkner will discuss AppyScore™, the company’s blood-based human diagnostic tests designed as an aid in the diagnosis of human appendicitis. The presentation will be available via webcast at http://www.wsw.com/webcast/roth20/appy.

As the company’s new executive chairman, Faulkner brings to AspenBio more than 25 years’ experience in developing and commercializing medical devices, drug and drug delivery systems, life science research tools, and molecular diagnostics.

For more information, please visit the conference website at www.rothconference.com or call a ROTH representative at 800-933-6830.

About ROTH Capital Partners, LLC

With corporate headquarters in Newport Beach, California and offices in strategic locations in the Western United States and Shanghai, China, ROTH Capital Partners, LLC is a full service investment bank serving corporate and institutional clients throughout the world. Offering a wide array of investment banking services including: initial public offerings, follow-ons, PIPEs, private placements, mergers and acquisitions, investment research, and institutional sales and trading, the firm is perhaps best known for finding, funding and fostering the growth of emerging companies. It is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and the Securities Investor Protection Corporation (SIPC). Visit the ROTH Capital Partners website at www.roth.com.

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to advance the development and testing of its three first-generation blood-based human diagnostic tests designed as an aid in the diagnosis of human appendicitis. For more information, go to www.aspenbiopharma.com.